Determination of immunoglobulin M antibodies for hepatitis B core antigen with a capture enzyme immunoassay and biotin-labeled core antigen produced in Escherichia coli

A two-particle turbidometric latex immunoassay for the detection of specific IgM antibodies

A simple two stage assay using latex particles as a reaction indicator has been developed for the detection of IgM antibodies to Trichinella spiralis. In the first stage, magnetic polystyrene beads (Dynabeads) coated with T. spiralis antigen were incubated for 30 min with the test serum. After washing, in the second stage, the assay was developed for 1 h using anti-mu-coated latex particles. After sedimentation of the Dynabeads the turbidity of the resultant latex suspension was measured spectrophotometrically at a wavelength of 400 nm. A decrease in turbidity of more than 20% from that of the control, unreacted, suspension was considered positive. Using an IgM phosphorylcholine-binding monoclonal antibody which was reactive with T. spiralis, the sensitivity of the assay was determined to be 110 ng/ml of antibody. This was 20-fold less than the sensitivity achieved in an indirect enzyme-linked immunosorbent assay (ELISA). When the assay was applied to sera obtained from CBA/N or BALB/c mice, which were either normal or immunized against T. spiralis, the expected results were obtained with titers up to 1/640 observed, and confirmed (r = 0.93, P less than 0.001) in the ELISA.

Hepatitis B virus DNA in blood specimens of anti HBc IgM positive patients

This study compares the presence of hepatitis B virus (HBV) DNA and HBV e antigen in sera positive for IgM antibody to HBV core antigen. Of the 31 sera included in the study, 14 were HBV DNA positive. Eight sera were positive for HBV DNA but negative for HBeAg and 3 sera were negative for HBV DNA but positive for HBeAg. The HBV DNA positive specimens included also 3 HBsAg negative sera. The importance of the level of the anti HBc IgM antibody is discussed.

The detection of measles specific immunoglobulin M antibodies using biotinylated antigens

The methods of reverse type enzymeimmunoassay (EIAs) with biotinylated antigens were used to determine IgM antibodies to measles virus in human sera. These antigens, either purified measles virus antigen or lysate type measles-vero antigen with lysate vero control antigen, were used in the two separate IgM-tests. Paired sera from 15 measles patients as well as 456 sera from patients with viral infections other than measles, with mycoplasma pneumoniae infections, from rheumatoid arthritis patients and blood donors, were assayed in a dilution of 1:200. Both the test systems detected all the 30 serum specimens from the measles patients as measles IgM positive, but the sera of all the other groups proved to be measles IgM negative. These tests developed for measles specific IgM antibodies, avoiding the interference of IgM-class rheumatoid factor, offer valuable tools for routine virus serology.

Diagnostic significance of anti-HBcIgM prevalence related to symptoms in Canadian patients acutely or chronically infected with hepatitis B virus

A total of 362 sera from 295 Canadian patients were examined for HBsAg, anti-HBs, anti-HBc, anti-HBcIgM, HBeAg, and anti-HBe using commercial immunoassays. Serial samples from 70 acutely infected patients demonstrated that anti-HBcIgM may detect 10% more positives than HBsAg within 4 months after the onset of clinical symptoms, and all except two were negative for anti-HBcIgM after the fourth month. None of 66 asymptomatic (HBeAg rate 18.2%) and two of 14 (14.3%) symptomatic (HBeAg rate 64.3%) carriers of HBsAg were positive for anti-HBcIgM (P = 0.029). Elevated marker responses were measured in two symptomatic carriers for a 20-month period. Anti-HBcIgM was not detected in either 100 asymptomatic patients positive for total anti-HBc, negative for HBsAg and negative for or possessing low levels of anti-HBs, 25 patients with liver disorders not caused by HBV, or 20 healthy milk donors. In diagnostic laboratory practice this anti-HBcIgM test may be useful in the following situations: to supplement HBsAg testing, providing a theoretical 10% increase in positives within 4 months following onset of acute viral hepatitis; to replace testing for anti-HBc and anti-HBs in symptomatic HBsAg-negative patients; to confirm whether a patient is experiencing acute or chronic HBV infection or symptoms superimposed upon asymptomatic HBsAg carriage by another cause, such as nonA-nonB viral hepatitis.